Professor Yaohe Wang

Professor Yaohe Wang

MD, PhD
Centre: Molecular Oncology
Professor of Cancer Cell and Gene Therapy
This email address is being protected from spambots. You need JavaScript enabled to view it.

QMUL Directory


We work on cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses, in particular focusing on replicating adenovirus and vaccinia virus.

Research Details

The major research interest in my group is developing new cancer immunotherapy agents or/and approaches through comprehensive investigations into the interaction of oncolytic viruses, tumour cells, tumour microenvironment and host immune responses.

Our four main research areas of interests are:

  • Identification of potential targets for the development of novel cancer cell and gene therapies
  • Development of new generation viral vectors for cell and gene therapies, in particular focusing on adenovirus, vaccinia virus and adeno-associated virus
  • Development of personalised cancer vaccines and adoptive T cell transfer therapies, such as CAR-T and TCR-T therapies for cancer
  • Development of genetically modified cancer models, in particular focusing on the development of transgenic Syrian hamster cancer models.

Profile

I qualified in medicine and obtained my PhD in 1997. From 1999 to 2005, I undertook postdoctoral research in molecular biology of cancer as well as cancer viral and genetic therapy at the MRC Toxicology Unit in Leicester University and the Cancer Research UK Molecular Oncology Unit based at Imperial College London.

I joined the Barts Cancer Institute (formerly Institute of Cancer) on 1st July 2005 as a Lecturer. I was promoted to a senior Lecturer and subsequently Reader in Molecular Oncology in 2007 and 2011, respectively, and became Professor of Cancer Cell and Gene Therapy in 2015.

I established the first Sino-British Research Centre for Molecular Oncology with Prof Nick Lemoine in 2006. The Centre was a joint venture entity between Queen Mary University of London and Zhengzhou University. The Centre was elected as a National Centre for International Research in Cell and Gene Therapy by the Ministry of Science and Technology of China in 2014. I have been appointed as the Director of the Centre since then.

I have been working in cancer virotherapy since 2001 with a substantial track record of publications in prestigious scientific journals such as “Nature Biotechnology”, “The Journal of Clinical Investigation (JCI)”, “Gut”, and “Nature Communications”, etc.

My long-term research aim is to develop more effective cancer cell and gene therapies based on the genetically engineered oncolytic virus platform, for prevention, diagnosis and treatment of human cancer, and advance them into clinical testing.

Funding

  • 2019-2022- Cancer Research UK Biotherapeutic Drug Development Fund, 'Development of a novel "super" Vaccinia virus, VV-PC21, for the treatment of pancreatic cancer,' £500,000
  • 2018-2021- Pancreatic Cancer Research Fund Project Grant, 'Personalised T-cell receptor based adoptive T-cell transfer therapy for human pancreatic cancer,' £200,000
  • 2017-2020- Pancreatic Cancer UK Grand Challenge award, 'Developing advanced CAR-T cell-based immunotherapies to improve the outcome of patients with pancreatic cancer,' £994,525 (£261,000 awarded to Prof Wang)
  • 2017-2020- William Harvey Research Ltd CRF fund, 'Improved treatment strategy for advanced pancreatic cancer,' £300,000
  • 2016-2019- The MRC DPFS grant, 'Development of an effective therapeutic regimen for treatment of advanced pancreatic cancer using a novel immunotherapeutic agent,' £576,701
  • 2015-2018- The MRC DPFS grant, 'Development of an effective therapeutic regimen for preventing cancer recurrence after surgery using a novel viro-immunotherapeutic agent,' £496,133
  • 2015-2018- Breast Cancer Now Project Grant, 'Development of an effective vaccine regimen particularly targeting triple-negative breast cancer,' £200,000

Key Publications

Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Pengju Wang, Xiaozhu Li, Jiwei Wang, Dongling Gao, Yuenan Li, Haoze Li, Yongchao Chu, Zhongxian Zhang, Hongtao Liu, Guozhong Jiang, Shengdian Wang, Nicholas R Lemoine and Yaohe Wang. Nature communications (2017) 8(1): 1395. PMID: 29123084

A Vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. Chard SL, Maniati E, Wang P, Zhang Z, Gao D, Wang J, Cao F, Ahmed J, Khouri M EI, Hughes J, Wang S, Li X, Denes B, Fodor I, Hageman T, Lemoine NR, Wang Y*. Clin Cancer Res (2015) 21(2): 405-16. PMID: 25416195

A novel therapeutic regime to eradicate established solid tumors with an effective induction of tumor-specific immunity. Tysome JR, Li X, Wang S, Wang P, Gao D, Du P, Chen D, Gangeswaran R, Chard LS, Yuan M, Alusi G, Lemoine NR, Wang Y*. Clin Cancer Res (2012) 18(24):6679-89. PMID: 23091113

CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells. Wang Y, Gangeswaran R, Zhao X, Wang P, Tysome J, Bhakta V, Yuan M, Chikkanna-Gowda CP, Jiang G, Gao D, Cao F, Francis J, Yu J, Liu K, Yang H, Zhang Y, Zang W, Chelala C, Dong Z, Lemoine N. J Clin Invest (2009) 119(6):1604-15. PMID: 19411761

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumour models. Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J, Brooks G, Lemoine N, Kirn D. Nature Biotechnology (2003) 21(11): 1328-35. PMID: 14555956


Further Publications

For additional publications, please click here.


We work on cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses, in particular focusing on replicating adenovirus and vaccinia virus.

External Activities

  • 2005-present- Visiting Professor in Cancer Viral and Genetic Therapy, Zhengzhou University of China
  • 2006-present- Chief Scientific Officer, Sino-British Research Centre for Molecular Oncology, Zhengzhou University, China
  • 2014-present- Director of National Centre for International Research in Cell and Gene Therapy, Zhengzhou University
  • 2014-present- Editorial Board member of Molecular Therapy-Oncolytics
  • 2008-2010- Editorial Board member of Gene Therapy
  • 2018-present- Standing Committee Member of Asia-Pacific Gene and Therapy Consortium
  • 2018-present- Founding Chairman of Syrian Hamster Disease Models Association
  • 2005-present- Active Member of American Society of Gene Therapy
  • 2011-present- Active Member of American Society of Microbiology
  • Research grant Assessor for grant awarding bodies: European Research Council, British Medical Research Council (MRC), The Wellcome Trust, Cancer Research UK, AICR, Ministry of Science and Technology, Netherland, International Association of Cancer Research, Natural Science Foundation of China and several UK Charities, Tenovus Charity.
  • Reviewers for scientific journals: Journal of Clinical Investigation, Cancer Research, Clinical Cancer Research, Molecular Therapy, Oncogene, J Path, Gene Therapy, Br J Cancer, Journal for immunotherapy of Cancer etc.

News

We are very interested in collaborations with scientists or companies to develop research tools (antibodies, gene sequencing, etc) for the Syrian Hamster model.

See other researchers working on:

Breast Gene Therapy Immunology Pancreas Viruses
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.